TARGOSAFE 400 INJECTION

Product Description

Product Name: TARGOSAFE 400 INJECTION
Composition: Teicoplanin 400mg
Category: Broad-Spectrum Antibiotic | Glycopeptide Antibiotic | Critical Care Injection

SEO-Optimized Product Description for Trade India & B2B Platforms:

TARGOSAFE 400 INJECTION contains Teicoplanin 400mg, a potent glycopeptide antibiotic used to treat a wide range of severe gram-positive bacterial infections, including MRSA, osteomyelitis, infective endocarditis, septicemia, and hospital-acquired infections. Known for its once-daily dosing, low nephrotoxicity, and high tissue penetration, TARGOSAFE 400 is a trusted option in ICU protocols and critical care treatment.

Manufactured under strict WHO-GMP and ISO-certified facilities, TARGOSAFE 400 INJ is ideal for bulk supply to hospitals, government tenders, and B2B pharmaceutical distribution networks.

Key Benefits:

• High-strength Teicoplanin 400mg for treating severe and resistant infections

• Effective against multi-drug resistant Gram-positive bacteria (e.g., MRSA)

• Administered via IV or IM injection

• Long half-life supports once-daily dosing regimen

• Preferred over vancomycin in cases requiring better renal safety

• Suitable for hospital use, ICUs, and surgical infection control

Product Specifications:

• Form: Sterile injectable powder with solvent

• Strength: 400mg per vial

• Packaging: Vial + ampoule (sterile water for reconstitution)

• Shelf Life: 24 months

• Storage: Store below 25C; protect from light and moisture

Target Audience:

• Hospital pharmacies & ICU procurement managers

• Pharmaceutical distributors & bulk buyers

• Government healthcare tenders & institutional supply chains

• Exporters of critical care injectables

For Business Enquiries:
Reach out to us for bulk orders, third-party manufacturing, and international export partnerships. We ensure stringent quality standards, competitive pricing, and timely logistics to meet your pharmaceutical supply needs globally.